Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2013

View Archived Issues

Inflection Biosciences and CNIO present novel dual PIM/PI3K and triple PIM/PI3K/mTOR inhibitors

Oxygen Biotherapeutics closes acquisition of Phyxius Pharma's levosimendan

UCI-50027 as a promising neuroactive steroid showing anticonvulsant and anxiolytic activity in vivo

Roche reports on discovery of a novel, direct-acting, RNA polymerase enzyme inhibitor to target HCV

Xofigo obtains marketing authorization in the E.U.

Ajinomoto patents novel integrin alpha4beta7 receptor antagonists

Toray Industries divulges novel soluble epoxide hydrolase inhibitors

Toyama Chemical scientists prepare and test deuterated antiviral agents

Yale University reports discovery of cytotoxic-drug-delivering molecules for HIV

Trk-A inhibitors reported in Ono Pharmaceutical patent

Global Genomics and Metabolon partner to discover cardiovascular disease biomarkers and drug targets

Cepheid presents early data for Xpert HPV test

FDA grants orphan drug designation to Epidiolex for Dravet syndrome

Baxter and Cell Therapeutics enter licensing agreement for pacritinib

ChanRx presents promising data from the COR-ART phase II trial

French ATU granted for Vimizim in Morquio A syndrome

Eisai forms partnership to make Halaven available in the Middle East

A novel KIT gene mutation identified in papillary thyroid carcinoma

Sanofi discontinues development of fedratinib over safety concerns

Akorn acquires U.S. rights to three ophthalmic products from Merck & Co.

BARDA exercises option for continued development of AverTox against nerve agents

FDA approves Valeant's Luzu for three fungal indications

Bayer, Inception Sciences and Versant Ventures establish ophthalmology collaboration

Tolerability and immunogenicity of the live attenuated tetravalent dengue vaccine candidate TV-003

Phase Ib trial for ATU-027 planned in head and neck squamous cell carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...